RT Book, Section
A1 Katzung, Bertram G.
A1 Kruidering-Hall, Marieke
A1 Tuan, Rupa Lalchandani
A1 Vanderah, Todd W.
A1 Trevor, Anthony J.
SR Print(0)
ID 1180558914
T1 Cancer Chemotherapy
T2 Katzung & Trevor's Pharmacology: Examination & Board Review, 13e
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260117127
LK accessmedicine.mhmedical.com/content.aspx?aid=1180558914
RD 2024/04/23
AB Cancer  chemotherapy  remains  a  challenging  area  of  pharmacology.  On  the  one  hand,  use  of  cytotoxic  anticancer  drugs  produces  high  rates  of  cure  of  a  few  cancers,  which,  without  chemotherapy,  result  in  extremely  high  mortality  rates  (eg,  acute  lymphocytic  leukemia  in  children,  testicular  cancer,  and  Hodgkin  lymphoma).  On  the  other  hand,  some  types  of  cancer  are  minimally  affected  by  currently  available  drugs.  Furthermore,  as  a  group,  the  cytotoxic  anticancer  drugs  are  more  toxic  than  any  other  drug  class  and  thus  their  benefit  must  be  carefully  weighed  against  their  risks.  Many  of  the  available  drugs  are  cytotoxic  agents  that  act  on  all  dividing  cells,  cancerous  or  normal.  The  ultimate  goal  in  cancer  chemotherapy  is  to  use  advances  in  cell  biology  to  develop  targeted  therapies  that  selectively  affect  specific  cancer  cells.  This  area  is  one  of  the  most  rapidly  expanding  fields  in  drug  development.